Methods and compositions for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions

A method for treating, preventing, inhibiting, ameliorating or delaying the onset of deterioration of ellipsoid zone integrity in one or more eyes of a mammalian subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one peptidomimetic, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof, wherein the peptidomimetic is a peptidomimetic of Formula I:

• wherein,
• AA1 is selected from
• AA2 is selected from
• R1 is selected from
• R2a is selected from
• R2b is H or CH3;
• R3 and R4 are independently selected from H and (C1-C6)alkyl;
• R5 and R6 are independently H, methyl, ethyl, propyl, cyclopropyl, or cyclobutyl;
• or R5 and R6 together with the N atom to which they are attached form a 4-6-membered heterocyclyl;
• R7 is selected from H, (C1-C6)alkyl, cycloalkyl, and aryl;
• R8 and R9 are independently selected from H, (C1-C6)alkyl, cycloalkyl, and aryl;
• or R8 and R9 together with the N atom to which they are attached form a 4-6-membered heterocyclyl;
• m is 1, 2, or 3;
• n is 1, 2, or 3;
• p is 0 or 1;
• X is selected from
• and
• * denotes the point of attachment of X to R1, and wherein one or more of the hydrogen atoms of the peptidomimetic is optionally substituted with a deuterium or fluorine atom.

A method for treating, preventing, inhibiting, ameliorating or delaying the onset of geographic atrophy a mammalian subject in need thereof where the subject has been diagnosed with age-related macular degeneration (AMD), comprising administering to the subject a therapeutically effective amount of at least one peptidomimetic, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof, wherein the peptidomimetic is a peptidomimetic of Formula I:

• wherein,
• AA1 is selected from
• AA2 is selected from
• R1 is selected from
• R2a is selected from
• R2b is H or CH3;
• R3 and R4 are independently selected from H and (C1-C6)alkyl;
• R5 and R6 are independently H, methyl, ethyl, propyl, cyclopropyl, or cyclobutyl;
• or R5 and R6 together with the N atom to which they are attached form a 4-6-membered heterocyclyl;
• R7 is selected from H, (C1-C6)alkyl, cycloalkyl, and aryl;
• R8 and R9 are independently selected from H, (C1-C6)alkyl, cycloalkyl, and aryl;
• or R8 and R9 together with the N atom to which they are attached form a 4-6-membered heterocyclyl;
• m is 1, 2, or 3;
• n is 1, 2, or 3;
• p is 0 or 1;
• X is selected from
• and
• * denotes the point of attachment of X to R1, and wherein one or more of the hydrogen atoms of the peptidomimetic is optionally substituted with a deuterium or fluorine atom.

A method for treating, preventing, inhibiting, ameliorating or delaying the onset of age-related macular degeneration in a mammalian subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one peptidomimetic, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof, wherein the peptidomimetic is a peptidomimetic of Formula I:

• wherein,
• AA1 is selected from
• AA2 is selected from
• R1 is selected from
• R2a is selected from
• R2b is H or CH3;
• R3 and R4 are independently selected from H and (C1-C6)alkyl;
• R5 and R6 are independently H, methyl, ethyl, propyl, cyclopropyl, or cyclobutyl;
• or R5 and R6 together with the N atom to which they are attached form a 4-6-membered heterocyclyl;
• R7 is selected from H, (C1-C6)alkyl, cycloalkyl, and aryl;
• R8 and R9 are independently selected from H, (C1-C6)alkyl, cycloalkyl, and aryl;
• or R8 and R9 together with the N atom to which they are attached form a 4-6-membered heterocyclyl;
• m is 1, 2, or 3;
• n is 1, 2, or 3;
• p is 0 or 1;
• X is selected from
• and
• * denotes the point of attachment of X to R1, and wherein one or more of the hydrogen atoms of the peptidomimetic is optionally substituted with a deuterium or fluorine atom.